Patients with COVID-19-induced ARDS have higher serum levels of endothelial damage markers such as angiopoietin-2, intercellular adhesion molecule-1, vascular cell adhesion molecule-1, P-selectin, and E-selectin than patients with other types of ARDS [127]. This evidence concerns the gene ICAM1 and COVID-19.